IsoPlexis Corporation Logo

IsoPlexis Corporation

ISO

(0.8)
Stock Price

0,76 USD

-61.25% ROA

-95.25% ROE

-0.55x PER

Market Cap.

30.283.577,00 USD

125.23% DER

0% Yield

-696.74% NPM

IsoPlexis Corporation Stock Analysis

IsoPlexis Corporation Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

IsoPlexis Corporation Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (0.73x), the stock offers substantial upside potential at a bargain price.

2 Graham Number

The Graham number calculation reveals that this company's stock price is potentially underestimated, implying that it may be a promising investment option.

3 ROE

The stock's ROE indicates a negative return (-138.99%) on shareholders' equity, suggesting poor financial performance.

4 ROA

The stock's ROA (-124.61%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

5 DER

The stock is burdened with a heavy load of debt (125%), making it financially unstable and potentially risky for investors.

6 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

IsoPlexis Corporation Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

IsoPlexis Corporation Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Sell

IsoPlexis Corporation Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

IsoPlexis Corporation Revenue
Year Revenue Growth
2019 7.505.000
2020 10.387.000 27.75%
2021 17.258.000 39.81%
2022 13.444.000 -28.37%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

IsoPlexis Corporation Research and Development Expenses
Year Research and Development Expenses Growth
2019 10.134.000
2020 11.157.000 9.17%
2021 20.966.000 46.79%
2022 20.580.000 -1.88%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

IsoPlexis Corporation General and Administrative Expenses
Year General and Administrative Expenses Growth
2019 4.806.000
2020 8.023.000 40.1%
2021 26.349.000 69.55%
2022 55.900.000 52.86%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

IsoPlexis Corporation EBITDA
Year EBITDA Growth
2019 -13.117.000
2020 -22.279.000 41.12%
2021 -75.644.000 70.55%
2022 -122.564.000 38.28%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

IsoPlexis Corporation Gross Profit
Year Gross Profit Growth
2019 4.247.000
2020 5.413.000 21.54%
2021 8.766.000 38.25%
2022 -31.256.000 128.05%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

IsoPlexis Corporation Net Profit
Year Net Profit Growth
2019 -13.627.000
2020 -23.285.000 41.48%
2021 -83.559.000 72.13%
2022 -138.876.000 39.83%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

IsoPlexis Corporation Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2019 0
2020 -1 0%
2021 -8 100%
2022 -4 -166.67%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

IsoPlexis Corporation Free Cashflow
Year Free Cashflow Growth
2001 0
2019 -17.136.000 100%
2020 -24.729.000 30.7%
2021 -110.730.000 77.67%
2022 -15.745.000 -603.27%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

IsoPlexis Corporation Operating Cashflow
Year Operating Cashflow Growth
2001 0
2019 -14.958.000 100%
2020 -22.434.000 33.32%
2021 -86.507.000 74.07%
2022 -15.478.000 -458.9%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

IsoPlexis Corporation Capital Expenditure
Year Capital Expenditure Growth
2001 0
2019 2.178.000 100%
2020 2.295.000 5.1%
2021 24.223.000 90.53%
2022 267.000 -8972.28%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

IsoPlexis Corporation Equity
Year Equity Growth
2019 35.050.000
2020 92.209.000 61.99%
2021 142.245.000 35.18%
2022 41.267.000 -244.69%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

IsoPlexis Corporation Assets
Year Assets Growth
2019 37.886.000
2020 123.605.000 69.35%
2021 187.472.000 34.07%
2022 109.068.000 -71.89%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

IsoPlexis Corporation Liabilities
Year Liabilities Growth
2019 2.836.000
2020 31.396.000 90.97%
2021 45.227.000 30.58%
2022 67.801.000 33.29%

IsoPlexis Corporation Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.2
Net Income per Share
-1.39
Price to Earning Ratio
-0.55x
Price To Sales Ratio
3.86x
POCF Ratio
-0.92
PFCF Ratio
-0.88
Price to Book Ratio
0.73
EV to Sales
5.67
EV Over EBITDA
-0.97
EV to Operating CashFlow
-1.37
EV to FreeCashFlow
-1.29
Earnings Yield
-1.83
FreeCashFlow Yield
-1.14
Market Cap
0,03 Bil.
Enterprise Value
0,04 Bil.
Graham Number
5.73
Graham NetNet
-0.34

Income Statement Metrics

Net Income per Share
-1.39
Income Quality
0.63
ROE
-0.95
Return On Assets
-0.5
Return On Capital Employed
-0.53
Net Income per EBT
1.06
EBT Per Ebit
1.07
Ebit per Revenue
-6.14
Effective Tax Rate
-0.06

Margins

Sales, General, & Administrative to Revenue
2.9
Research & Developement to Revenue
1.19
Stock Based Compensation to Revenue
0.27
Gross Profit Margin
-0.71
Operating Profit Margin
-6.14
Pretax Profit Margin
-6.59
Net Profit Margin
-6.97

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.82
Free CashFlow per Share
-0.88
Capex to Operating CashFlow
0.06
Capex to Revenue
-0.26
Capex to Depreciation
-0.84
Return on Invested Capital
-0.52
Return on Tangible Assets
-0.61
Days Sales Outstanding
209.46
Days Payables Outstanding
75.77
Days of Inventory on Hand
749.39
Receivables Turnover
1.74
Payables Turnover
4.82
Inventory Turnover
0.49
Capex per Share
-0.05

Balance Sheet

Cash per Share
0,95
Book Value per Share
1,05
Tangible Book Value per Share
0.55
Shareholders Equity per Share
1.05
Interest Debt per Share
1.39
Debt to Equity
1.25
Debt to Assets
0.47
Net Debt to EBITDA
-0.31
Current Ratio
4.06
Tangible Asset Value
0,02 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
1.25
Working Capital
0,05 Bil.
Intangibles to Total Assets
0.18
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
32881500
Debt to Market Cap
1.71

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

IsoPlexis Corporation Dividends
Year Dividends Growth

IsoPlexis Corporation Profile

About IsoPlexis Corporation

IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States, Canada, the United Kingdom, Belgium, France, the Czech Republic, Spain, Germany, Sweden, Italy, Israel, Switzerland, China and Taiwan, Singapore, Japan, Australia, and Korea. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.

CEO
Mr. Sean Mackay
Employee
290
Address
35 NE Industrial Road
Branford, 06405

IsoPlexis Corporation Executives & BODs

IsoPlexis Corporation Executives & BODs
# Name Age
1 Mr. Anthony Catalano
Senior Vice President of Operations
70
2 Mr. John R. Strahley CPA
Chief Financial Officer
70
3 Ms. Carrie Carter
Senior Vice President of People Operations
70
4 Mr. Richard W. Rew II
Senior Vice President, Gen. Counsel & Sec.
70
5 Ms. Jing Zhou M.D., Ph.D.
Chief Scientific Officer
70
6 Mr. Rong Fan
Co-Founder & Chairman of Scientific Advisory Board
70
7 Ms. Verna Siu
Senior Vice President of Sales Operations
70
8 Mr. Sean Mackay
Co-Founder, Chief Executive Officer, Pres & Director
70
9 Mr. Rajesh T. Khakhar
Vice President of Fin. & Principal Accounting Officer
70

IsoPlexis Corporation Competitors